v3.26.1
Earnings (loss) per share (Tables)
 12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Earnings per Share
 
 
Basic and diluted earnings (loss) per share attributable to Teva’s ordinary shareholders for the years ended December 31, 2025, 2024 and 2023 are calculated as follows:
 
 
  
Years ended December 31,
 
 
  
 2025 
 
  
 2024 
 
  
 2023 
 
 
  
(In millions, except per share amounts)
 
Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
         
Net income (loss) attributable to Teva’s ordinary shareholders
    $ 1,410      $ (1,639 )     $ (559 ) 
  
 
 
     
 
 
     
 
 
  
Shares (denominator):
         
Weighted average shares outstanding
      1,145        1,131        1,119  
  
 
 
     
 
 
     
 
 
  
Basic earnings (loss) attributable to Teva’s ordinary shareholders
    $ 1.23      $ (1.45 )     $ (0.50 ) 
  
 
 
     
 
 
     
 
 
  
Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
         
Net income (loss) attributable to Teva’s ordinary shareholders
    $ 1,410      $ (1,639 )     $ (559 ) 
  
 
 
     
 
 
     
 
 
  
Shares (denominator):
         
Weighted average shares outstanding
      1,145        1,131        1,119  
Diluted effect of stock options, RSUs and PSUs
      17        —         —   
Total dilutive shares outstanding
      1,163        1,131        1,119  
  
 
 
     
 
 
     
 
 
  
Diluted earnings (loss) attributable to Teva’s ordinary shareholders
    $ 1.21      $ (1.45 )     $ (0.50 )